QT Imaging Holdings (QTI) Shareholder presentation summary

Commercial progress

• H1 2026 revenue was $14.0M, up 116% YoY; 28 Breast Acoustic CT scanners shipped, double the H1 2025 total.

• More than 12,000 women have been imaged; FY 2026 revenue guidance is approximately $39M, following $18.9M in 2025 and $4.9M in 2024.

• Expanded direct U.S. sales with two regional leaders, alongside NXC Imaging distribution; the strategy is to evolve toward a hybrid model with direct strategic-account coverage.

• International partners include Gulf Medical in Saudi Arabia, Al Naghi Medical in the UAE, and Re-Invent Pharma in Pakistan; regulatory authorizations were secured in Saudi Arabia, the UAE, and Israel.

Financial and operational foundation

• Completed a $10M underwritten public offering, extended senior secured term-loan maturity to March 31, 2029, and had $14.2M in cash and restricted cash as of August 7, 2026.

• Returned to the Nasdaq Capital Market and joined the Russell Microcap Index, increasing visibility among institutional investors and index-tracking funds.

• Entered an agreement to move headquarters and manufacturing to a 22,000-square-foot Petaluma facility, providing more than 2.5x current space and ~55% lower lease cost per square foot.

• Completed the first routine FDA inspection with zero Form 483 observations.

Regulatory and reimbursement progress

• Two FDA clearances expanded scanner capabilities, including improved posterior breast coverage and software supporting volumetric measurements for lesion doubling-time assessment.

• An AMA Category III CPT code for 3D quantitative breast ultrasound tomography was released July 1, 2026, and becomes effective January 1, 2027, establishing a framework for reporting and evidence development.

• International authorizations in Saudi Arabia, the UAE, and Israel expanded the platform’s commercial regulatory foundation.